Cargando…
CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
Inactivating p53 mutations are the most abundant genetic alterations found in cancer. Here we show that CRISPR/Cas9-induced double-stranded DNA breaks enrich for cells deficient in p53 and in genes of a core CRISPR–p53 tumor suppressor interactome. Such enrichment could predispose to cancer developm...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9397613/ https://www.ncbi.nlm.nih.gov/pubmed/34750099 http://dx.doi.org/10.1158/0008-5472.CAN-21-1692 |
_version_ | 1784772158046601216 |
---|---|
author | Jiang, Long Ingelshed, Katrine Shen, Yunbing Boddul, Sanjaykumar V. Iyer, Vaishnavi Srinivasan Kasza, Zsolt Sedimbi, Saikiran Lane, David P. Wermeling, Fredrik |
author_facet | Jiang, Long Ingelshed, Katrine Shen, Yunbing Boddul, Sanjaykumar V. Iyer, Vaishnavi Srinivasan Kasza, Zsolt Sedimbi, Saikiran Lane, David P. Wermeling, Fredrik |
author_sort | Jiang, Long |
collection | PubMed |
description | Inactivating p53 mutations are the most abundant genetic alterations found in cancer. Here we show that CRISPR/Cas9-induced double-stranded DNA breaks enrich for cells deficient in p53 and in genes of a core CRISPR–p53 tumor suppressor interactome. Such enrichment could predispose to cancer development and thus pose a challenge for clinical CRISPR use. Transient p53 inhibition could suppress the enrichment of cells with these mutations. The level of DNA damage response induced by an sgRNA influenced the enrichment of p53-deficient cells and could be a relevant parameter in sgRNA design to limit cellular enrichment. Furthermore, a dataset of >800 human cancer cell lines identified additional factors influencing the enrichment of p53-mutated cells, including strong baseline CDKN1A expression as a predictor for an active CRISPR–p53 axis. Taken together, these data provide details about p53 biology in the context of CRISPR-induced DNA damage and identify strategies to enable safer CRISPR use. SIGNIFICANCE: CRISPR-mediated DNA damage enriches for cells with escape mutations in a core CRISPR–p53 interactome, which can be suppressed by transient inhibition of p53. |
format | Online Article Text |
id | pubmed-9397613 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Association for Cancer Research |
record_format | MEDLINE/PubMed |
spelling | pubmed-93976132023-01-05 CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies Jiang, Long Ingelshed, Katrine Shen, Yunbing Boddul, Sanjaykumar V. Iyer, Vaishnavi Srinivasan Kasza, Zsolt Sedimbi, Saikiran Lane, David P. Wermeling, Fredrik Cancer Res Genome and Epigenome Inactivating p53 mutations are the most abundant genetic alterations found in cancer. Here we show that CRISPR/Cas9-induced double-stranded DNA breaks enrich for cells deficient in p53 and in genes of a core CRISPR–p53 tumor suppressor interactome. Such enrichment could predispose to cancer development and thus pose a challenge for clinical CRISPR use. Transient p53 inhibition could suppress the enrichment of cells with these mutations. The level of DNA damage response induced by an sgRNA influenced the enrichment of p53-deficient cells and could be a relevant parameter in sgRNA design to limit cellular enrichment. Furthermore, a dataset of >800 human cancer cell lines identified additional factors influencing the enrichment of p53-mutated cells, including strong baseline CDKN1A expression as a predictor for an active CRISPR–p53 axis. Taken together, these data provide details about p53 biology in the context of CRISPR-induced DNA damage and identify strategies to enable safer CRISPR use. SIGNIFICANCE: CRISPR-mediated DNA damage enriches for cells with escape mutations in a core CRISPR–p53 interactome, which can be suppressed by transient inhibition of p53. American Association for Cancer Research 2022-01-01 2021-11-18 /pmc/articles/PMC9397613/ /pubmed/34750099 http://dx.doi.org/10.1158/0008-5472.CAN-21-1692 Text en ©2021 The Authors; Published by the American Association for Cancer Research https://creativecommons.org/licenses/by-nc-nd/4.0/This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. |
spellingShingle | Genome and Epigenome Jiang, Long Ingelshed, Katrine Shen, Yunbing Boddul, Sanjaykumar V. Iyer, Vaishnavi Srinivasan Kasza, Zsolt Sedimbi, Saikiran Lane, David P. Wermeling, Fredrik CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies |
title | CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies |
title_full | CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies |
title_fullStr | CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies |
title_full_unstemmed | CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies |
title_short | CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies |
title_sort | crispr/cas9-induced dna damage enriches for mutations in a p53-linked interactome: implications for crispr-based therapies |
topic | Genome and Epigenome |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9397613/ https://www.ncbi.nlm.nih.gov/pubmed/34750099 http://dx.doi.org/10.1158/0008-5472.CAN-21-1692 |
work_keys_str_mv | AT jianglong crisprcas9induceddnadamageenrichesformutationsinap53linkedinteractomeimplicationsforcrisprbasedtherapies AT ingelshedkatrine crisprcas9induceddnadamageenrichesformutationsinap53linkedinteractomeimplicationsforcrisprbasedtherapies AT shenyunbing crisprcas9induceddnadamageenrichesformutationsinap53linkedinteractomeimplicationsforcrisprbasedtherapies AT boddulsanjaykumarv crisprcas9induceddnadamageenrichesformutationsinap53linkedinteractomeimplicationsforcrisprbasedtherapies AT iyervaishnavisrinivasan crisprcas9induceddnadamageenrichesformutationsinap53linkedinteractomeimplicationsforcrisprbasedtherapies AT kaszazsolt crisprcas9induceddnadamageenrichesformutationsinap53linkedinteractomeimplicationsforcrisprbasedtherapies AT sedimbisaikiran crisprcas9induceddnadamageenrichesformutationsinap53linkedinteractomeimplicationsforcrisprbasedtherapies AT lanedavidp crisprcas9induceddnadamageenrichesformutationsinap53linkedinteractomeimplicationsforcrisprbasedtherapies AT wermelingfredrik crisprcas9induceddnadamageenrichesformutationsinap53linkedinteractomeimplicationsforcrisprbasedtherapies |